US Patent

US7344702 — Contrast agents for myocardial perfusion imaging

Composition of Matter · Assigned to Bristol Myers Squibb Pharma Co · Expires 2026-05-26 · 0y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds and methods for imaging myocardial perfusion using a contrast agent that binds MC-1 and includes an imaging moiety.

USPTO Abstract

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Drugs covered by this patent

Patent Metadata

Patent number: US7344702
Jurisdiction: US
Classification: Composition of Matter
Expires: 2026-05-26
Drug substance claim: Yes
Drug product claim: No
Assignee: Bristol Myers Squibb Pharma Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.